GSTP1, PRDX2 and NFE2L2: Potential Markers for Primary Stage Breast Cancer

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Rising breast cancer incidence and mortality necessitate early detection methods.
• Early diagnosis is crucial for effective breast cancer management.
• Identifying novel biomarkers for early-stage breast cancer is a key research focus.

Purpose of the Study:

• To identify and quantify oxidative stress-related proteins as potential early-stage breast cancer markers.
• To investigate the differential expression of specific proteins and microRNAs in breast cancer tissues.
• To evaluate the potential of these biomarkers in early breast cancer diagnosis.

Main Methods:

• Proteomic analysis of normal and cancerous breast tissue samples (n=40) using a label-free approach.
• Quantification of gene expression for GSTP1, PRDX2, HSP90, NFE2L2, and miR-365a via RT-qPCR.
• Immunohistochemical analysis of PRDX2 and GSTP1 protein expression.

Main Results:

• GSTP1, PRDX2, and HSP90 showed significant upregulation in cancerous tissues at both gene and protein levels (p < 0.05).
• NFE2L2 gene and protein expression was significantly downregulated in cancerous samples (p < 0.05).
• OncomiR-365a was significantly upregulated in cancerous tissues (p < 0.05).

Conclusions:

• GSTP1, PRDX2, and NFE2L2 play significant roles in breast cancer pathophysiology and may serve as early-stage diagnostic markers.
• Altered expression of these proteins could indicate a protective role in mitigating cellular damage.
• These proteins represent potential therapeutic targets for breast cancer treatment.